Published in Cancer Weekly, June 5th, 2006
Revenue for the first quarter of 2006 was $25,000 compared to $57,000 for the quarter ended March 31, 2005. Revenue in 2006 includes recognition of deferred revenue related to two license agreements.
Dendreon's total operating expenses for the three months ended March 31, 2006 were $25.5 million compared to $20.6 million for the same period in 2005. Operating expenses for the three months ended March 31, 2006 included stock-based employee compensation expense of $801,000.
The net loss for the quarter ended March 31, 2006 was $24.4 million, or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.